Publications 2000-2011

Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E.

Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharmacol. 2005 Aug 2; 57(4):491-9

Raymond E, Kahatt C, Rigolet MH, Sutherland W, Lokiec F, Alexandre J, Tombal B, Elman M, Lee MS, MacDonald JR, Cullen M, Misset JL, Cvitkovic E.

Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials. Clin Cancer Res. 2004 Nov 15;10(22):7566-74. Erratum in: Clin Cancer Res. 2005 Feb 15; 11(4):1684.

Licitra L, Bernier J, Cvitkovic E, Grandi C, Spinazze S, Bruzzi P, Gatta G, Molinari R.

Cancer of the nasopharynx. Crit Rev Oncol Hematol. 2003 Feb; 45(2):199-213. Review.

Alexandre J, Raymond E, Kaci MO, Brain EC, Lokiec F, Kahatt C, Faivre S, Yovine A, Goldwasser F, Smith SL, MacDonald JR, Misset JL, Cvitkovic E.

Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. Clin Cancer Res. 2004 May 15; 10(10):3377-85.

Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E , Misset JL.

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004 Mar 1;22(5):890-9.

Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P.

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol. 2004 Mar; 15(3):467-73.

Droz JP, Muracciole X, Mottet N, Ould Kaci M, Vannetzel JM, Albin N, Culine S, Rodier JM, Misset JL, Mackenzie S, Cvitkovic E, Benoit G.

Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol. 2003 Aug; 14(8):1291-8.

Urien S, Alexandre J, Raymond E, Brain E, Smith S, Shah A, Cvitkovic E, Lokiec F.

Phase I population pharmacokinetics of irofulven. Anticancer Drugs. 2003 Jun; 14(5):353-8.

Poindessous V, Koeppel F, Raymond E, Cvitkovic E, Waters SJ, Larsen AK.

Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. Int J Oncol. 2003 Nov; 23(5):1347-55.

Monnet I, de CH, Soulie P, Saltiel-Voisin S, Bekradda M, Saltiel JC, Brain E, Rixe O, Yataghene Y, Misset JL, Cvitkovic E.

Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Annals of Oncology 13. 2002 Jan; 13(1):103-7.

Menashi S, Serova M, Ma L, Vignot S, Mourah S, Calvo F.

Regulation of Extracellular Matrix Metalloproteinase Inducer and Matrix Metalloproteinase Expression by Amphiregulin in Transformed Human Breast Epithelial Cells. Cancer Research. 2003. V.63 (22). P. 7575-7580.

Mita C, Chatelut E, Bekradda M, Soulie P, Canal P, Misset JL, Cvitkovic E, Bugat R.

Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies. Annals Oncology 14. 2003;14(12):1776-82.